Recommendations for the treatment of established fungal infections - PubMed (original) (raw)
Practice Guideline
Recommendations for the treatment of established fungal infections
K A Thursky et al. Intern Med J. 2008 Jun.
Abstract
Evidence-based guidelines for the treatment of established fungal infections in the adult haematology/oncology setting were developed by a national consensus working group representing clinicians, pharmacists and microbiologists. These updated guidelines replace the previous guidelines published in the Internal Medicine Journal by Slavin et al. in 2004. The guidelines are pathogen-specific and cover the treatment of the most common fungal infections including candidiasis, aspergillosis, cryptococcosis, zygomycosis, fusariosis, scedosporiosis, and dermatophytosis. Recommendations are provided for management of refractory disease or salvage therapies, and special sites of infections such as the cerebral nervous system and the eye. Because of the widespread use newer broad-spectrum triazoles in prophylaxis and empiric therapy, these guidelines should be implemented in concert with the updated prophylaxis and empiric therapy guidelines published by this group.
Similar articles
- Antifungal therapy in invasive fungal infections.
Chen SC, Playford EG, Sorrell TC. Chen SC, et al. Curr Opin Pharmacol. 2010 Oct;10(5):522-30. doi: 10.1016/j.coph.2010.06.002. Epub 2010 Jul 2. Curr Opin Pharmacol. 2010. PMID: 20598943 Review. - Newer antifungal agents for invasive fungal infections in patients with haematological malignancy.
Rogers TR, Frost S. Rogers TR, et al. Br J Haematol. 2009 Mar;144(5):629-41. doi: 10.1111/j.1365-2141.2008.07412.x. Epub 2008 Dec 11. Br J Haematol. 2009. PMID: 19120371 Review. - Systemic fungal infections: major problems in cancer patients.
Powles RL, Mehta J. Powles RL, et al. Indian J Cancer. 1994 Sep;31(3):180-4. Indian J Cancer. 1994. PMID: 8557296 Review.
Cited by
- Development and Validation of Voriconazole Concentration by LC-MS-MS: Applied in Clinical Implementation.
Prommas S, Puangpetch A, Jenjirattithigarn N, Chuwongwattana S, Jantararoungtong T, Koomdee N, Santon S, Chamnanphon M, Sukasem C. Prommas S, et al. J Clin Lab Anal. 2017 Jan;31(1):e22011. doi: 10.1002/jcla.22011. Epub 2016 Jun 24. J Clin Lab Anal. 2017. PMID: 27337994 Free PMC article. - Immediate versus deferred empirical antifungal (IDEA) therapy in high-risk patients with febrile neutropenia: a randomized, double-blind, placebo-controlled, multicenter study.
Maschmeyer G, Heinz WJ, Hertenstein B, Horst HA, Requadt C, Wagner T, Cornely OA, Löffler J, Ruhnke M; IDEA study investigators. Maschmeyer G, et al. Eur J Clin Microbiol Infect Dis. 2013 May;32(5):679-89. doi: 10.1007/s10096-012-1794-4. Epub 2012 Dec 28. Eur J Clin Microbiol Infect Dis. 2013. PMID: 23271674 Clinical Trial. - Pharmacokinetics of voriconazole administered concomitantly with fluconazole and population-based simulation for sequential use.
Damle B, Varma MV, Wood N. Damle B, et al. Antimicrob Agents Chemother. 2011 Nov;55(11):5172-7. doi: 10.1128/AAC.00423-11. Epub 2011 Aug 29. Antimicrob Agents Chemother. 2011. PMID: 21876043 Free PMC article. Clinical Trial. - Management of invasive candidiasis in the intensive care unit.
Playford EG, Lipman J, Sorrell TC. Playford EG, et al. Drugs. 2010 May 7;70(7):823-39. doi: 10.2165/10898550-000000000-00000. Drugs. 2010. PMID: 20426495 - Determinants of mortality in non-neutropenic ICU patients with candidaemia.
Marriott DJ, Playford EG, Chen S, Slavin M, Nguyen Q, Ellis D, Sorrell TC; Australian Candidaemia Study. Marriott DJ, et al. Crit Care. 2009;13(4):R115. doi: 10.1186/cc7964. Epub 2009 Jul 13. Crit Care. 2009. PMID: 19594912 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical